<DOC>
	<DOCNO>NCT01649375</DOCNO>
	<brief_summary>This study ass efficacy safety secukinumab patient active ankylose spondylitis tolerant inadequate response NSAIDs , DMARDs / TNFα inhibitor</brief_summary>
	<brief_title>16 Week Efficacy 5 Year Long Term Efficacy , Safety Tolerability Secukinumab Patients With Active Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male nonpregnant , nonlactating female patient Diagnosis moderate severe AS prior document radiologic evidence ( xray ) fulfil Modified New York criterion AS ( 1984 ) Patients NSAIDs inadequate response Patients regularly take NSAIDs part AS therapy require stable dose Patients antiTNFα agent ( one ) must experience inadequate response Chest Xray ( MRI ) evidence ongoing infectious malignant process Patients total ankylosis spine Patients previously treat biological immunomodulating agent except target TNFα Previous treatment celldepleting therapy Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Ankylosing spondylitis</keyword>
	<keyword>AS</keyword>
	<keyword>Chronic inflammatory disease</keyword>
	<keyword>Inflammatory back pain</keyword>
	<keyword>Secukinumab</keyword>
	<keyword>Prefilled syringe ( PFS )</keyword>
	<keyword>Subcutaneous injection</keyword>
	<keyword>AIN457</keyword>
	<keyword>AIN457F</keyword>
	<keyword>AIN457F2310</keyword>
</DOC>